treatment outcome according to tumor ras mutation status in crystal study patients with metastatic...

21

Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Upload: morris-fitzgerald

Post on 18-Jan-2016

220 views

Category:

Documents

0 download

Report

Download

Tags:

Embed Size (px):

TRANSCRIPT

Page 1: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without

Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 2: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without

Disclosure Information<br />Relationships Relevant to this Session

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 3: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without

CRYSTAL study design

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 4: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without

Background

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 5: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without

RAS mutation analysis: BEAMing

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 6: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without

RAS mutation analysis: BEAMing

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 7: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without

Study profile

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 8: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without

Other RAS mutations: CRYSTAL

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 9: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without

Other RAS mutations: first-line studies

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 10: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without

Comparison of RAS subgroups: <br />efficacy

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 11: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without

Baseline characteristics

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 12: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without

Efficacy: RAS subgroups

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 13: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without

Efficacy: RAS subgroups

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 14: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without

Progression-free survival

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 15: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without

Progression-free survival

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 16: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without

Overall survival

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 17: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without

Overall survival

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 18: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without

Efficacy: RAS subgroups

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 19: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without

Safety: grade 3/4 adverse events

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 20: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without

Conclusions

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 21: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without

Acknowledgments

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev as 1st-line treatment of metastatic colorectal cancer: results of the phase III randomized TRIBE trial

Independent radiological evaluation of objective response ... · N=592 Final RAS evaluable population N= 475 FOLFIRI Cetuximab N= 297 FOLFIRI Bevacizumab N= 295 FOLFIRI Cetuximab

FOLFOX4 (12 cycles) versus sequential dose-dense FOLFOX7 (6 cycles) followed by FOLFIRI (6 cycles) in patients with initially resectable metastatic colorectal

ECCO 2009 GI Update: Focus on EGFR Inhibitors in Metastatic Colorectal CA (mCRC)

MCRC Staff Training 2010 What is MCRC?. Session Overview

FOLFOXIRI plus bevacizumab (BV) vs FOLFIRI plus BV as first- line treatment of metastatic colorectal cancer (MCRC): preliminary safety results of the phase

ISSN 1948-5204 World Journal of · 2018. 12. 14. · that FOLFOXIRI plus bevacizumab is more beneficial than FOLFIRI plus bevacizumab as first-line treatment in patients with metastatic

COLORECTAL CANCER RESEARCH & PRACTICE UPDATES · 2020. 5. 11. · bevacizumab among patients with previously untreated metastatic colorectal cancer (mCRC). First -line FOLFOXIRI plus

Defined Health is pleased to present · metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test Bevacizumab, mCRC Doxorubicin liposomal, Kaposi’s

Diagnosed with Metastatic Colorectal Cancer?...Surgery Surgery can be a treatment option for some patients who have been diagnosed with mCRC. There are several areas of the body where

Immunotherapy in metastatic colorectal cancer (mCRC ...cpo-media.net/ECP/2019/Congress-Presentations/16/MSI TA Nice.pdf · 3 Bevacizumab Overall Survival) BSC 5-FU 30 Irinotecan

iDSI Indonesia – Mission Report - globalhitap.net fileJKN Jaminan Kesehatan Nasional, the universal healthcare program mCRC Metastatic Colorectal Cancer MoH Ministry of Health, Indonesia

MCRC Submission Report

FOLFOXIRI/ bevacizumab ( bev ) versus FOLFIRI/ bev as first-line treatment in unresectable metastatic

FIRE 3 Trail FOLFIRI+Cetuximab Vs FOLFIRI+Bevacizumab

III RANDOMIZED “TRIBE - gislides.com FOLFOXIRI_BEV... · folfoxiri plus bevacizumab (bv) vs folfiri plus bv as first-line treatment of metastatic colorectal cancer (mcrc): preliminary

Company’s · Metastatic Colorectal Cancer (mCRC) patients can be treated with: ̶Conventional Chemotherapy (5 FU, Irinotecan, Oxaliplatin, FolFox, Folfiri) ̶Targeted therapies

Randomized Phase III Trial of Cetuximab Plus Irinotecan vs Irinotecan Alone for Metastatic Colorectal Cancer (mCRC) after Failing Prior Oxaliplatin-based

Department of Investigational Cancer Therapeutics Phase I ...€¦ · metastatic colorectal cancer (mCRC). J Clin Oncol 2019;37(4_suppl):688. 4. Kopetz S, McDonough SL, Morris VK,

Annual Report 2010-11 - MCRC

ThePursuit ofMarginalIndications anda Me·Too …alo.mit.edu/wp-content/uploads/2015/06/Unitended...OS Criteria d Ziv-Aflibercept 6B 8/3/2012 1226 Second-line mCRC; with FOLFIRI 2.2

CURRENT STATUS AND FUTURE OUTLOOK FOR BIOSIMILARS · Ovarian cancer (EU only) 2004, 2006 . 2009 . 2011 . Erbitux ( cetuximab) Chimeric IgG1 . EGFR . mCRC . ... Metastatic breast cancer

Phase III CORRECT trial of regorafenib in metastatic colorectal cancer ( mCRC )

Veridex, LLC Metastatic Prostate Cancer K07333Metastatic Prostate Cancer Metastatic Colorectal Cancer (MCRC) A total 1,627 duplicate blood samples were collected from 430 MCRC patients

Update on Antiangiogenic Therapy for Metastatic … · 1 | The Angiogenesis Foundation Metastatic colorectal cancer (mCRC) is the third leading cause of cancer-related deaths in the

ASCO 2012 Effects of Prior Bevacizumab Use on Outcomes From the VELOUR Study: A Phase 3 Study of Aflibercept and FOLFIRI in Patients With Metastatic Colorectal

Www.OncologyEducation.ca KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights … · second-line treatment of patients with metastatic colorectal cancer (mCRC). Avastin, in combination with fluoropyrimidine-irinotecan-

Chemotherapyand targeted agentsin 1st line · Metastatic Palliation Acute 5-FU BSC Palliation Chronic Multidisciplinary Multi ‘optional’ Curative 6 months > 5 years mCRC (R)Evolution

Predictive value of skin-toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): a pooled analysis of 5 clinical

YOUR ROLE AS A SHE’S BEEN RIGHT THERE Additional resources ... · • Metastatic colorectal cancer (mCRC) ... Web resource providing timely, oncologist-approved information from

Presentation1 for ies- mcrc

Review of the ESMO consensus conference on metastatic ... · Waiting for PANDA. 1st line treatment of mCRC: ESMO consensus guidelines Van Cutsem et al ... ESMO/Pan-Asian consensus